ArticleBioactive materials2025
Self-assembling peptide inspired by insulin and type 1 insulin-like growth factor for the treatment of androgenetic alopecia.
Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Self-assembling biomimetic peptide hydrogel regulates tissue homeostasis to promote repair of persistent corneal epithelial defects.Bioactive materials · 2026Article
- A dual-mechanism injectable hydrogel integrating reactive oxygen species regulationand low-level laser therapy for androgenetic alopecia remediation.Journal of nanobiotechnology · 2026Article
- Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia.Frontiers in pharmacology · 2026Review
- Enzyme-Instructed Self-Assembly for Cellular Supramolecular Chemistry.Chemistry, an Asian journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgenetic alopecia (AGA), the most prevalent form of hair loss, urgently requires breakthroughs in existing therapies due to limitations such as medication side effects, recurrence risks, and treatment inefficacy. Herein, we propose an insulin-derived self-assembling sequence Ac-GFFY, combined with the C domain peptide of insulin-like growth factor 1, successfully designing an IGF-1 biomimetic peptide factor, Ac-GFFY-IGF, which can substitute for the absent IGF-1 in the AGA pathological environment and facilitate hair regrowth. Compared with IGF-1, Ac-GFFY-IGF exhibits superior
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.